Spero Therapeutics, Inc.
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, includingā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.22
Price+0.83%
$0.01
1Y
Price
Market Cap
$70.640m
Small
Price/Earnings 3y Avg5y Avg
5.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2791.9%
EBITDA Margin-2791.9%
Net Profit Margin+6148.8%
Free Cash Flow Margin-2791.9%
EBITDA Margin-2791.9%
Net Profit Margin+6148.8%
Free Cash Flow MarginRevenue
$54.766m
-8.1%
1y CAGR-12.5%
3y CAGR+19.0%
5y CAGREarnings
$15.235m
+77.7%
1y CAGR-70.1%
3y CAGR-15.3%
5y CAGREPS
$0.24
+60.0%
1y CAGR-74.5%
3y CAGR-22.1%
5y CAGRBook Value
$52.934m
$59.021m
Assets$6.087m
Liabilities$2.474m
DebtDebt to Assets
4.2%
0.2x
Debt to EBITDAFree Cash Flow
$7.242m
+157.4%
1y CAGR+77.5%
3y CAGR-23.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company